DOCSLIB.ORG

Otsuka Group CSR Report 2012

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Otsuka Group CSR Report 2012 Otsuka Group CSR Report 2012 Otsuka-people creating new products for better health worldwide OTSUKA GROUP Editorial Policy CSR REPORT 2012 On December 15, 2010, Otsuka Holdings Co., Ltd. became a public company by listing its shares on the First Section of the Tokyo Stock Exchange. In keeping with its corporate com- mitment to “Otsuka-people creating new products for better health worldwide,” the Otsuka Group endeavors to leverage its unique assets and skills to have a positive impact on health worldwide through its business. We published our fi rst environmental and social report in 2010, in order to provide diverse stakeholders with information about the many initiatives that the Group pursues through its business. Starting in 2011, we expanded the scope of the report to broadly inform stakehold- ers about the Group’s corporate social responsibility (CSR) efforts. In this report, we focused on providing stakeholders with a more comprehensive picture of initiatives that are being pursued throughout the Otsuka Group with several common themes. We have gathered information from Group companies around the world to report on social ini- tiatives, and focused on securing the accuracy and continuity of environmental performance data. Furthermore, the knowledge that was gained from assembling this report will be lever- aged to expand future CSR initiatives of the Otsuka Group. Scope of report This report focuses on Otsuka Holdings. The social initiatives described in this report encompass the global activities of Group companies in and outside Japan. Environmental data applies to the following 11 Group companies in Japan: Otsuka Pharmaceutical Co., Ltd. JIMRO Co., Ltd. Otsuka Pharmaceutical Factory, Inc. EN Otsuka Pharmaceutical Co., Ltd. TAIHO PHARMACEUTICAL CO., LTD. Otsuka Techno Corporation Otsuka Warehouse Co., Ltd. Otsuka Packaging Industries Co., Ltd. Otsuka Chemical Co., Ltd. Otsuka Foods Co., Ltd. Otsuka Electronics Co., Ltd. Period covered The data presented in this report are actual fi gures from April 1, 2011 to March 31, 2012. The activities reported on include some conducted more recently. Publication schedule The next report is scheduled for publication in autumn 2013. Guidelines referenced This report was compiled with reference to the Environmental Report Guidelines 2007 Edition and the Environmental Accounting Guidelines 2005 Edition issued by Japan’s Ministry of the Environment, and the GRI Sustainability Reporting Guidelines 3rd Edition. Feedback on the Otsuka Group CSR Report We welcome your feedback by email. Please do not hesitate to provide us with your feedback or impressions of this report, including requests about the initiatives of the Otsuka Group. Your input is valuable and will help us shape future reports and initiatives. Email [email protected] 01 OTSUKA GROUP CSR REPORT 2012 Corporate Profi le Contents About the Otsuka Group As of March 31, 2012 Company name: Otsuka Holdings Co., Ltd. About the Otsuka Group …………… 02 Established: July 8, 2008 Corporate Profi le …………………………………… 02 Capital: JPY 81.69 billion Otsuka Group across the Globe ………… 03 Head Offi ce: 2-9 Kanda-Tsukasamachi, Business Overview of the Otsuka Group …………………………………… 05 Chiyoda-ku Tokyo 101-0048, Japan the President Message from Tokyo Headquarters: Shinagawa Grand Central Tower, 2-16-4 Konan, Minato-ku, Tokyo 108-8241, Japan Message from the President …… 07 Representative: Tatsuo Higuchi, President and Representative Director, CEO Corporate Philosophy …………………………… 10 Employees: 65 (Consolidated: 24,595) Scope of consolidation: 67 consolidated subsidiaries and 13 equity method affi liates Highlight 1 Business description: Control, management, and other operational aspects of Tackling Unmet business activities related to holding the shares of companies Medical Needs …………………………………… 11 that operate in the fi elds of pharmaceuticals, nutraceuticals, Developing New Pharmaceuticals consumer products, and other businesses. Highlight Highlight 2 Soylution-From Japan to the World …………………………………………… Consolidated Net Sales Consolidated Operating Income 13 A New Solution for Environmental Issues and Operating income Better Health Worldwide (Unit: ¥ billion) Net sales (Unit: ¥ billion) (%) Operating margin 1,200 1,127.6 1,154.6 160 16 1,084.3 148.7 140 15 Highlight 3 1,000 928.5 955.9 126.3 118.3 120 14 Community and Social Report 800 98.5 100 91.5 13 Global Initiatives ………………………………… 15 600 80 12.9 12 The World's Only Museum Displaying Masterpieces 12.7 60 11 on Ceramic Panels-Otsuka Museum of Art 400 11.2 40 10 200 20 9.6 9 …………………………………… 9.1 Social Report 19 0 0 8 FY2007 FY2008 FY2009 FY2010 FY2011 FY2007 FY2008 FY2009 FY2010 FY2011 Managing and Improving Quality ………… 21 Environmental Report Environmental Social Initiatives for Better Health ………… 23 Consolidated Ordinary Income Research and Development Expenses Ordinary income R&D expenses Social Contribution Activities— (Unit: ¥ billion) (%) (Unit: ¥ billion) (%) Operating margin Operating margin Otsuka Group and Local Communities ……… 25 160 152.1 16 180 17 164.7 159.2 160 151.8 16 Building Vital Workplaces 140 128.4 15 124.1 for Employees ………………………………………… 31 140 135.9 15 120 109.1 14 120 14 Development of Human Capital …………… 100 96.1 13 14.6 33 101.8 14.0 13.4 13.2 100 14.2 13.8 13 80 12 Employee Health ……………………………………… 34 80 12 60 11 11.4 60 11 40 10 40 11.0 10 10.1 10.1 ………………… Management 20 9 20 9 Environmental Report 35 0 8 0 8 Environmental Performance Data ……… 37 FY2007 FY2008 FY2009 FY2010 FY2011 FY2007 FY2008 FY2009 FY2010 FY2011 Note: Data marked “FY2007” is from the consolidated earnings of Otsuka Pharmaceutical. Energy and Resource Conservation …… 39 Zero-Emissions Initiatives ……………………… 42 Consolidated Net Sales Consolidated Net Sales by Geographical Segment (FY2011) by Business Segment (FY2011) Coexistence with Nature ……………………… 43 Sales to external customers Sales to external customers Performance Data Environmental Clean-Up Activities ………………………………… 45 Others: 73.1 Consumer Products: Other: Pharmaceuticals: Japan: 48.0 782.2 166.2 574.9 6.3% Management ……………………………………… 47 14.4% 4.2% Corporate Governance …………………………… 49 21.8% Risk Management …………………………………… 50 49.8% Compliance ……………………………………………… 51 35.8% 67.7% Third-Party Opinion / Editorial Postscript ………………………………… 52 North America: 413.5 Nutraceuticals: 251.3 Environmental Performance Data ………… 53 (Unit: ¥ billion) (Unit: ¥ billion) OTSUKA GROUP CSR REPORT 2012 02 Otsuka Group across the Globe The Otsuka Group’s global businesses create a variety of products that help to maintain and enhance daily health and aid in the diagnosis and treatment of illness. As of March 31, 2012, net sales from markets outside Japan accounted for 50% of the Group’s consolidated net sales. There are approximately 25,000 employees in the consolidated Group worldwide, and 44% of these are outside Japan. Otsuka Group employees are working every day around the world, for the universal betterment of human health. Asia and Europe Middle East Japan 1,402 6,803 13,808 employees employees employees 20 26 19 companies companies companies Belgium China Japan Nutrition & Sante Benelux SA Otsuka (China) Investment Co., Ltd. Otsuka Holdings Co., Ltd. Zhejiang Otsuka Pharmaceutical Co., Ltd. Otsuka Pharmaceutical Co., Ltd. France Sichuan Otsuka Pharmaceutical Co., Ltd. Otsuka Pharmaceutical Factory, Inc. Otsuka Pharmaceutical France SAS Tianjin Otsuka Beverage Co., Ltd. TAIHO PHARMACEUTICAL CO., LTD. Euriso-Top S.A.S Suzhou Otsuka Pharmaceutical Co., Ltd. Otsuka Warehouse Co., Ltd. Nardobel SAS Shanghai Otsuka Foods Co., Ltd. Otsuka Chemical Co., Ltd. Nutrition & Sante SAS Chongqing Otsuka Huayi Chemical Co., Ltd. Otsuka Medical Devices Co., Ltd. Nutrition & Nature SAS China Otsuka Pharmaceutical Co., Ltd.* EN Otsuka Pharmaceutical Co., Ltd. Laboratoires Dietetique et Sante SAS Guangdong Otsuka Pharmaceutical Co., Ltd.* Otsuka Electronics Co., Ltd. ALMA S.A.* Micro Port Medical (Shanghai) Co., Ltd.* Otsuka Techno Corporation Microport Scientifi c Corporation* J.O. Pharma Co., Ltd. Germany VV Food & Beverage Co., Ltd.* OKAYAMA TAIHO PHARMACEUTICAL CO., LTD. Otsuka Pharma GmbH Otsuka Packaging Industries Co., Ltd. Cambridge Isotope Laboratories (Europe), GmbH Egypt Otsuka Foods Co., Ltd. Euriso-Top GmbH Egypt Otsuka Pharmaceutical Co., S.A.E. Otsuka Chilled Foods Co., Ltd. Advanced Biochemical Compounds, GmbH Otsuka-MGC Chemical Company, Inc. India JIMRO Co., Ltd. Italy Otsuka Chemical (India) Private Limited Earth Chemical Co., Ltd.* Nutrition & Sante Italia SpA Earth Environmental Service Co., Ltd.* Indonesia Spain P.T. Otsuka Indonesia Otsuka Pharmaceutical, S.A. P.T. Merapi Utama Pharma Nutrition & Sante Iberia SL P.T. Widatra Bhakti Hebron S.A. P.T. Amerta Indah Otsuka P.T. Otsuka Jaya Indah Sweden P.T. Lautan Otsuka Chemical Otsuka Pharma Scandinavia AB Switzerland South Korea Thailand Nutrinat AG Korea Otsuka Pharmaceutical Co., Ltd. Thai Otsuka Pharmaceutical Co., Ltd.* Dong-A Otsuka Co., Ltd.* UK Otsuka Pharmaceutical Europe, Ltd. Taiwan Pakistan Otsuka Pharmaceutical (U.K.) Ltd. Taiwan Otsuka Pharmaceutical Co., Ltd. Otsuka Pakistan Ltd.* King Car Otsuka Co., Ltd.* * List of consolidated companies. Equity-method affi liates are indicated with an asterisk (*). 03 OTSUKA GROUP CSR REPORT 2012 About the Otsuka Group North America 2,582 employees 15 companies Canada Otsuka Canada Pharmaceutical Inc. 2768691 Canada, Inc. USA Otsuka America, Inc. Otsuka America Pharmaceutical, Inc. Otsuka Pharmaceutical Development & Commercialization, Inc. Otsuka Maryland Medicinal Laboratories,
Load more

Recommended publications
  • Awa Life June 2012.Indd
    阿波ライフ 264 July AWA LIFE A monthly newsletter for the international residents of Tokushima Prefecture, produced Walk it out, Toppy by TOPIA, the Tokushima Prefectural International Exchange Association. bird watching in Tokushima Richard Ingham An introduction to some of Tokushima's feathery inhabitants eaves of houses and convenience stores. The nests are built from mud and a little straw, all held together with a bit of swallow saliva. Japanese people consider it good luck if swallows nest in their houses, and locals treat the nests carefully, sometimes positioning a small cardboard box underneath the nest to prevent the sidewalk from becoming caked in swallow droppings! A brood of six chicks is considered to bring particular good fortune and some Japanese Barn Swallow nest families are known to cook Bird-watching dozen species to spot in your celebratory portions of red rice ( 赤 area and life gets so much more 飯 ) when the young birds finally fulfills our interesting when you are aware fly the nest. After having raised primeval hunting of the wildlife around you. So, a brood or two, the parents and instincts. It which birds can the novice see (or their offspring will leave in late hear) in and around Tokushima? summer, flying several thousand delivers all the miles to return to their wintering thrill of the chase, Barn swallows ( ツバメ燕 ) grounds in Southeast Asia. even though the arrived back in Japan at the end of March, and when they are not You may hear a piercing shriek prey itself escapes swooping to catch insects you whilst travelling around Tokushima unharmed.
    [Show full text]
  • Product Japan : Food Processing Sector - Health and Functional Foods Company Profiles
    Foreign Agricultural Service GAIN Report Global Agriculture Information Network Approved by: Date: 07/23/99 Sarah D. Hanson GAIN Report #JA9087 U.S. Embassy Market Brief - Product Japan : Food Processing Sector - Health and Functional Foods Company Profiles This report was prepared by the USDA’s Foreign Agricultural Service for U.S. exporters of food and agricultural products. This information is in the public domain and may be reprinted without permission. Use of commercial or trade names does not imply approval nor constitute endorsement by USDA/FAS. Tokyo[JA1], JA GAIN Report #JA9087 Page 1 of 24 Company Name Amway Japan Product Sector(s) Health and Functional Food Address 1-8-1, Shimo-Meguro Number Of Employees 728 Meguro-ku, Tokyo 153-8686 Number of Factories Overseas Contact Phone Number 03-5434-8484 Fax Number 03-5434-4923 Email Web Page Address www.amway.co.jp/amway_japan/ Contact Person Masura Iwata Executive Driector, External Affairs and Public Relations Sales and Net Profits Main Suppliers Year Sales (Mil. \) Net Profits 1995 177,991 22,424 1996 212,195 25,130 1997 203,361 26,638 Key Products % of Total Company Profile and Strategies Home Care Products 9 Japanese corporation of nonstore sales operator Amway (US). Housewares 30 Registered sales personnel involved in direct sales of detergents, Personal Care 34 cosmetics, kitchenware and nutritional supplements. Nutritional Supplements 23 Others 4 Main Brands Triple X (vitamin and mineral supplement), Nutri Protein, Acerola C (vitamin supplement), Salmon-Omega 3, Hon-E-Cece, Ironics, Beta Carotene A, Wheat Germ E. Main Ingredients Vitamins, protein concentrates, iron concentrates, calcium concentrates, beta caroten, wheat germ.
    [Show full text]
  • An Empirical Study on New Product Introductions in the Japanese Soft-Drink Industry
    Who Imitates Whom? An Empirical Study on New Product Introductions in the Japanese Soft-drink Industry Shigeru Asaba Gakushuin University Department of Economics 1-5-1 Mejiro Toshima-ku Tokyo, 171-8588 JAPAN E-mail: [email protected] Tel: +81-3-5992-3649 FAX: +81-3-5992-1007 Marvin B. Lieberman The Anderson School at UCLA Box 951481 Los Angeles, CA 90095-1481 E-mail: [email protected] Tel: 310-206-7665 Fax: 310-206-3337 February 19, 2011 1 Who Imitates Whom? A Study on New Product Introductions in the Japanese Soft-drink Industry ABSTRACT Imitation is observed in various contexts in the business world and numerous theories on imitation have been proposed. Incumbent theories on imitation are organized into two broad categories: information-based theories and rivalry-based theories. Information-based theories propose that firms follow others that are perceived as having superior information. Rivalry-based theories propose that firms imitate others to maintain competitive parity or limit rivalry. This study tries to distinguish among the theories by examining when and what kinds of firms are more likely to be followed by others in their new product introductions in the Japanese soft-drink industry. The empirical analysis shows that in brand-new product imitation, firms follow large competitors, while in product proliferation within established product categories, firms do not tend to follow large firms but mimic others of similar size. These contrasting results are reasonable, suggesting that two theories on imitation coexist and environmental uncertainty may be one of key distinguishing characteristics. In the case of brand-new products, firms face much uncertainty.
    [Show full text]
  • Japan Energy and Sports Drink Market: Sample Report
    1 © This is a licensed product of Ken Research and should not be copied TABLE OF CONTENTS 1. Asia Energy and Sports Drinks Market Introduction 2. Asia Energy and Sports Drinks Market Size, 2007-2012 3. Japan Energy and Sports Drinks Market Introduction 4. Japan Energy and Sports Drinks Market Size, 2007-2012 5. Japan Energy and Sports Drinks Market Segmentation by Functionality, 2007-2012 5.1. For Consumers at Work, 2007-2017 5.2. For Consumers at Play, 2007-2017 5.3. For Consumers at Leisure, 2007-2017 6. Japan Quasi Drug Energy Drink Market Segmentation by Distribution Channel, 2007-2012 6.1. For Drug Stores, 2007-2017 6.2. For Convenience Stores, 2007-2017 6.3. For Supermarkets and Hypermarkets, 2007-2017 6.4. For Others (Small Independent Retailers and Conventional Grocery Stores), 2007-2017 7. Japan Energy Drink Market Segmentation by Distribution Channel, 2007-2012 7.1. For Vending Machines, 2007-2017 7.2. For Convenience Stores, 2007-2017 7.3. For Supermarkets and Hypermarkets, 2007-2017 7.4. For Others (Small Independent Shops and Retailers), 2007-2017 8. Japan Sports Drink Market Segmentation by Distribution Channel, 2007-2012 8.1. For Hypermarkets and Supermarkets, 2007-2017 8.2. For Convenience Stores, 2007-2017 8.3. For Vending Machines, 2007-2017 8.4. For Others (Small Independent Retailers and Grocery Stores), 2007-2017 9. Japan Energy and Sports Drinks Market Trends and Developments Surge in the Number of Vending Machines in Japan Increasing Number of Fitness Clubs and Programs 2 © This is a licensed product of Ken Research and should not be copied Increase in the Expenditure on Food and Beverage Products 10.
    [Show full text]
  • Polskie Towarzystwo Technologów Żywności Wydawca Oddział Małopolski
    POLSKIE TOWARZYSTWO TECHNOLOGÓW ŻYWNOŚCI WYDAWCA ODDZIAŁ MAŁOPOLSKI ŻYWNOŚĆ NAUKA. TECHNOLOGIA. JAKOŚĆ Suplement Nr 4(21) Kraków 1999 Rok 6 ŻYWNOŚĆ Kwartalnik naukowy Nr 4(21) Supl. Kraków 1999 Rok 6 Zamieszczone artykuły są recenzowane Czasopismo jest referowane przez: AGRO-LIBREX, Chemical Abstracts Senice i IFIS POLSKIE TOWARZYSTWO TECHNOLOGÓW ŻYWNOŚCI WYDAWCA ODDZIAŁ MAŁOPOLSKI ŻYWNOŚĆ NAUKA«TECHNOLOGIA· JAKOŚĆ Suplement Nr 4(21) Kraków 1999 Rok 6 REDAKCJA: Redaktor naczelny: prof, dr hab. Tadeusz Sikora; tel./fax 012/ 4213834 Sekretarz redakcji: dr inż. Anna Bala-Piasek; tel. 012/ 411-91-44 w. 293; e-mail: [email protected] Redaktorzy: prof, dr hab. Bohdan Achremowicz, prof, dr hab. Mieczysław Pałasiński, dr inż. Jerzy Pałasiński, dr Teresa Woźniakiewicz Stali współpracownicy: prof, dr hab. Jacek Kijowski (Poznań), dr hab. Danuta Kołożyn-Krajewska (Warszawa), dr Grażyna Morkis (Warszawa), doc. dr hab. Maria Soral-Śmietana (Olsztyn) RADA PROGRAMOWA: prof, dr Antoni Rutkowski (przewodniczący), dr hab. Kazimierz Dąbrowski (sekretarz), prof, dr hab. Zbigniew Duda, prof, dr hab. Józef Fornal, prof, dr hab. Roman Grzybowski, prof, dr hab. Mieczysław Jankiewicz, prof, dr hab. Jan Kisza, prof, dr hab. Andrzej Lenart, prof, dr hab. Helena Oberman, prof, dr hab. Zdzisław E. Sikorski, prof, dr hab. Tadeusz Tuszyński, prof, dr hab. Stanisław Tyszkiewicz WYDAWCA: POLSKIE TOWARZYSTWO TECHNOLOGÓW ŻYWNOŚCI Oddział Małopolski © Copyright by Polskie Towarzystwo Technologów Żywności, Kraków 1999 Printed in Poland Wydawanie publikacji dofinansowane przez Komitet Badań Naukowych ISSN 1425-6959 ADRES REDAKCJI: 31-425 KRAKÓW, AL. 29 LISTOPADA 46 SKŁAD I DRUK: Wydawnictwo Naukowe „Akapit”, Kraków tel./fax (012) 266-92-69 ŻYWNOŚĆ 4(21)Supl„ 1999 SPIS TREŚCI Od R edakcji........................................................................................................................................................
    [Show full text]
  • Dear Participants of the 5Th World Congress on Alternatives And
    Abstracts001-Edi 24.07.2005 12:17 Uhr Seite 1 EDITORIAL Dear Participants of the 5th World Congress on Alternatives and Animal Use in the Life Sciences, The abstract book contains 614 abstracts of the plenary lectures of 272 oral presentations and 342 posters to be presented at the 5th World Congress on Alternatives in August 2005 in Berlin, Germany. The programme and the abstract book allow you to make your best selection of presentations among seven themes, which will be discussed in 29 sessions, 15 workshops and in the poster sessions. Usually, the first author of an abstract is slotted to give the oral presentation or to be present during the poster session to discuss your comments and questions. Otherwise, the presenting author is marked with an asterisk (*). We hope that you will find the abstracts particularly helpful to set priorities when two or more sessions are scheduled at the same time. In case you do not manage to attend a session or to meet an author, the contact addresses are given for each contributor. It is obvious from the list of sponsors, the programme and from the number of abstracts submitted that the most important topic of the 5th World Congress will be in vitro testing of cosmetic ingredients, in particular acute local toxicity testing. More abstracts have been submitted to sessions and workshops of Theme 5 “Safety testing, validation and risk assessment” than to any of the other themes. Moreover, more than 60 abstracts have been submitted to session 5.4 “Development and validation of alternatives for dermal toxicity testing”.
    [Show full text]
  • SHANNON G. AKEGARASU PRODUCER / LINE PRODUCER / 1St AD
    SHANNON G. AKEGARASU PRODUCER / LINE PRODUCER / 1st AD st EMPLOYMENT Producer & 1 AD. ”Run! Run! Run!” ASATSU-DK, Inc. / Shiseido “Secret Restaurant” McCann Erickson Japan / Nestle Purina Petcare “Green I.T.” x 2 Ricoh San-Ai Service / Ricoh “Girl Like You” WE Marketing Group / Blue Girl Beer “Ahead 2008” Shanghai Hakuhodo Advertising / Acura China “Accord 2007” Honda Commtec / Honda Co., Ltd “Tribeca 2007” ASATSU-DK Inc. / Subaru Japan “Platinum Dance Kauai w/ Ziyi Zhang” aeiou Shanghai / Platinum Guild International “Toyota Diving & Windsurfing Maui” Dentsu / Toyota Motor Corporation “Mitsui MD-1” ASATSU-DK Inc. / Mitsui Direct General Insurance Co., Ltd. “Westwood” Maxray Brand Communications / Shanghai Guo Guang Co. Ltd. “Blue Ice G550” S2C2 / Noevir Co., Ltd. “Happiness featuring Joanne” R&C Japan Ltd. / Yoshimoto Kogyo Co. “Day-Lee Pride x 3” S2C2 / Day-Lee Pride & Nippon Ham *& Director “Socratto on Porsche” S2C2 / Sony Co., Ltd. "Mayan Elder & Child" Hakuhodo / Kagome Co., Ltd. "Open Car" Ogilvy & Mather Japan / Ponds Japan "Noevir '01 x 2" S2C2 / Noevir Co., Ltd. *& Creative Director "Subaru 3 Keys VP" Dentsu / Subaru Japan "Nissan El Grand" Hakuhodo / Nissan Co., Ltd. "H.I.S. Can Do America!" Asatsu DK / H.I.S. "STM 2001 International*" S2C2 / Shiseido Co., Ltd. *& Editor "Noevir '00" Marz Network, Inc./Noevir Co.,Ltd.*& Creative Director “STM 2001 Launch*” S2C2 / Shiseido Co., Ltd. *& Scriptwriter “Robust Water” Publicis Ad - Link / Robust Group Co., Ltd. “Noevir ’99 vs 2” Marz Network, Inc. / Noevir Co., Ltd. “A View From Above” Ogilvy & Mather / Allied Property (HK) “Island Resort: More” Grant Advertising / Sino Land Co Ltd “Campbell’s Plant” Dentsu Y&R / Campbell’s Soup Asia “Canon / Tonight Show” Hakuhodo / Canon Inc.
    [Show full text]
  • Microrna Profiles Involved in Trifluridine Resistance
    www.impactjournals.com/oncotarget/ Oncotarget, 2017, Vol. 8, (No. 32), pp: 53017-53027 Research Paper MicroRNA profiles involved in trifluridine resistance Kenta Tsunekuni1,2,3,*, Masamitsu Konno1,4,*, Ayumu Asai1,2,4, Jun Koseki2, Takashi Kobunai3, Teiji Takechi3, Yuichiro Doki1, Masaki Mori1 and Hideshi Ishii1,2 1Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan 2Department of Medical Data Science, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan 3Translational Research Laboratory, Taiho Pharmaceutical Co, Ltd, Tokushima City, Tokushima, 771-0194, Japan 4Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan *These authors contributed equally to this work Correspondence to: Masaki Mori, email: [email protected] Hideshi Ishii, email: [email protected] Keywords: colorectal cancer, trifluridine, 5-fluorouracil, let-7d-5p, drug resistance Received: March 28, 2017 Accepted: May 09, 2017 Published: May 23, 2017 Copyright: Tsunekuni et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Trifluridine (FTD) is a key component of the novel oral antitumor drug trifluridine/tipiracil, which is approved for the treatment of patients with metastatic colorectal cancer refractory to standard chemotherapies. A microRNA analysis of three colorectal cell lines was conducted to investigate causes of FTD resistance. Drug resistant sublines of DLD-1, HCT-116, and RKO cells were developed by continuous administration of increasing doses of FTD for 5 months.
    [Show full text]
  • Gulfood Brochure 2020 Final Print Copy
    ___ 2020 ___ UAE . OMAN . BAHRAIN . KUWAIT . QATAR Our Values: Our values are part of our DNA. They guide the way we work with our business partners, within our communities & with each other. Our values define our culture & help us fulfill our mission. Our company values respect, integrity, excellence and teamwork. These values help the company to succeed & maintain a position as one of the most respectful company in the region. KUWAIT Our Mission: BAHRAIN Our deepest purpose as an organization is to improve business across the region with a goal to provide the highest level of services QATAR by providing the broadest selection of products and assuring a value that improves UNITED the lifestyle of the consumer. ARAB EMIRATES OMAN Network: Headquartered in the UAE, the Al Maya Group has strengthened its regional presence across Oman, Bahrain and Kuwait over the past two decades. Besides this the group has also been fortifying its global identity with stores in India and the United Kingdom. GROWING GLOBALLY SINCE 1982 Al Maya Group established in 1982 by a pioneering and inspiring businessman Late Mr. L.K Pagarani. The Group is a Dubai based conglomerate that has become a force to reckon within the industry. Today the Group employs more than 5,000 employees from 30 different countries for its multiple business verticals; the FMCG Distribution of Food and Non-Food products, Processing Plants in India and other countries around the world, over 90 retail stores in the UAE & GCC including Supermarkets, Borders and Paperchase. Why Al Maya? Over 40 years of successful market presence.
    [Show full text]
  • Facultad De Medicina
    FACULTAD DE MEDICINA LICENCIATURA EN NUTRICIÓN ANTOLOGIA DE SOCIOCULTURA ALIMENTARIA INÉS AIMME ITURBIDE PARDIÑAS ÍNDICE Índice……………………………………………………………………………………….3 Prólogo…………………………………………………………………………………….4 Introducción…………………………………………………………………….……….10 Tema 1 Debates actuales en la sociocultura de la alimentación………………14 Práctica 1………………………………………………………………………………...18 Tema 2 La importancia de la sociocultura de la alimentación en México……19 Práctica 2………………………………………………………………………………...22 Tema 3 La alimentación en México: Un estudio a partir de la encuesta……..26 Nacional de ingresos y gastos de los hogares Práctica 3………………………………………………………………………………...30 Tema 4 Alimentación y Religión……………………………………………………..31 Práctica 4………………………………………………………………………………...39 Tema 5 Aspectos sociales……………………………………………………………39 Práctica 5………………………………………………………………………………...43 Tema 6 Un vistazo a la cultura culinaria en México……………………………...43 Práctica 6………………………………………………………………………………...60 Tema 7 Armonización del vino con los alimentos………………………………..60 Práctica 7………………………………………………………………………………...77 Tema 8 Sociología de la alimentación alrededor del mundo…………………..78 2 Práctica 8………………………………………………………………………………...88 Tema 9 Un vistazo a la cocina Norteamericana…………………………………..90 Práctica 9……………………………………………………………………………….137 Tema 10 Un vistazo a la cocina China…………………………………………….138 Práctica 10……………………………………………………………………………..158 Tema 11 Un vistazo a la cocina Japonesa………………………………………..159 Práctica 11………………………………………………………………………….…..181 Tema 12 Un vistazo a la cocina Tailandesa……………………………………...182
    [Show full text]
  • Taiho Pharmaceutical
    Generating Innovation with Japan: BC 2021 - HealthTech Taiho Pharmaceutical Robert Tam, Director, Market Access March 9, 2021 Corporate Philosophy Company Profile Taiho Pharmaceutical, co. ltd ● Established June, 1963 ● Head Quarter Tokyo ● President & Representative Director Masayuki Kobayashi ● Employees 2,315 ● NET Sales ¥138.9B (US$1.3B) Others 8% Others Discovery CHC 9% Oncology 68% Clinical･MA Dermatology 5% CHC CMC Net Sales Employees Allergy n=2,315 10% ¥ 138.9 B Production Drug Sales (as of January 2019) QA 2 Offices and Facilities ● Head Office/Tokyo ● Branch Offices: 15 ・ Headquarter functions ・ Ethical drug: 15 ・ Clinical development ・ Consumer: 7 ・ QA ・ Medical affairs ・ Marketing Pharmaceutical value chain Drug Discovery Drug Development Manufacturing Sales & Marketing ● Research Institute: 2 ● Plants: 4 Tsukuba Saitama (API) Tokushima (Products) ・ Target identification U.S. Inspection U.S. Inspection European authorities Inspection ・ Lead optimization European authorities Inspection Tokushima Kitajima (Products) Inuyama (API) ・ Pre-clinical studies U.S. Inspection European authorities Inspection ・ CMC development OSDrC Tec 3 3 Taiho Subsidiary Companies Taiho Pharmaceutical Co., Ltd. Global Headquarters Taiho Pharmaceutical Taiho Oncology Europe, GmbH of Beijing Co., Ltd. Taiho Pharma Canada, Inc. Development, Sales Promotion/Clinical Sales Taiho Ventures LLC. Venture Capital Taiho Innovations LLC. Taiho Oncology, Inc. Venture Capital Sales/Clinical Okayama -Taiho Taiho Pharma Pharmaceutical Co., Ltd. Singapore Pte., Ltd. Research / Clinical / Sales Production / Sales 4 4 Overview of Otsuka Group ● Otsuka Group Profile 189 companies (162 subsidiaries and 26 affiliates , plus 1 company (Otsuka Holdings itself)) About 47,000 employees Global network: JP, Asia, MEA, Oceania, EU, NA, LA （as of December 31, 2018） ● Structure of Group Capital Otsuka Holdings Co., Ltd.
    [Show full text]
  • Health Canada Approves Inqovi® (Decitabine And
    HEALTH CANADA APPROVES INQOVI® (DECITABINE AND CEDAZURIDINE) ORAL THERAPY FOR TWO TYPES OF BLOOD CANCERS, MDS AND CMML • Oral drug can be taken at home, which may enable some patients to avoid some hospital visits • Treatment can induce complete remission and reduce blood transfusion needs for patientsi OAKVILLE, ON, OCTOBER 8, 2020 – Taiho Pharma Canada, Inc., the Canadian subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), today announces that Health Canada approved INQOVI® as the first and only orally administered hypomethylating agent for the treatment of adults with intermediate-1, intermediate-2 and high-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML),ii two blood malignancies. INQOVI was developed by Astex Pharmaceuticals, a sister company of Taiho and will be available in Canada. “INQOVI offers selected MDS patients an effective oral treatment alternative to the current standard 7 days of subcutaneous injections administered in a cancer centre every month,” says Dr. Rena Buckstein, Hematologist Oncologist at the Odette Cancer Centre at Sunnybrook Health Sciences Centre, Toronto, Ontario. “Having an oral option is very important for patients who cannot travel and is particularly significant during the COVID-19 pandemic when we try to minimize hospital visits to protect patients and medical staff.” “Canadian oncologists and patients were involved in the clinical development program for INQOVI with several clinical study sites,” said Dr. Mohammad Azab, President and Chief Medical Officer of Astex Pharmaceuticals. “We are thrilled that INQOVI is now available for healthcare professionals to prescribe to their patients across Canada living with MDS and CMML.” About MDS & CMML Myelodysplastic syndromes (MDS) are a group of diseases in which the bone marrow does not make enough healthy mature blood cells.
    [Show full text]